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All women undergo the menopause transition (MT), a neuro‑endocrinological process that impacts 
aging trajectories of multiple organ systems including brain. The MT occurs over time and is 
characterized by clinically defined stages with specific neurological symptoms. Yet, little is known 
of how this process impacts the human brain. This multi‑modality neuroimaging study indicates 
substantial differences in brain structure, connectivity, and energy metabolism across MT stages 
(pre‑menopause, peri‑menopause, and post‑menopause). These effects involved brain regions 
subserving higher‑order cognitive processes and were specific to menopausal endocrine aging rather 
than chronological aging, as determined by comparison to age‑matched males. Brain biomarkers 
largely stabilized post‑menopause, and gray matter volume (GMV) recovered in key brain regions for 
cognitive aging. Notably, GMV recovery and in vivo brain mitochondria ATP production correlated 
with preservation of cognitive performance post‑menopause, suggesting adaptive compensatory 
processes. In parallel to the adaptive process, amyloid‑β deposition was more pronounced in peri‑
menopausal and post‑menopausal women carrying apolipoprotein E‑4 (APOE‑4) genotype, the major 
genetic risk factor for late‑onset Alzheimer’s disease, relative to genotype‑matched males. These data 
show that human menopause is a dynamic neurological transition that significantly impacts brain 
structure, connectivity, and metabolic profile during midlife endocrine aging of the female brain.
The menopause transition (MT) is a midlife neuroendocrine aging process specific to females that culminates 
with reproductive  senescence1. All women undergo menopause in their lifetime either through the natural 
endocrine aging process or through medical intervention. The MT occurs in stages characterized by unique 
endocrine properties that impact aging trajectories of multiple organ systems including  brain1. While menopause 
is a reproductive transition state, it is also a neurological  transition1, as evidence by the fact that many menopausal 
symptoms are neurological in nature, such as hot flashes, disturbed sleep, mood changes, and  forgetfulness2.
The MT is orchestrated by gonadal sex steroid hormones, which are known regulators of both reproductive 
and neural  function1. During the MT, sex hormones, especially 17β-estradiol, substantially decline in body and 
 brain3. Molecular, cellular and systems biology characterization of the MT in brain demonstrate a broad impact of 
estrogen declines on neural processes via genomic and non-genomic  actions1, including changes in spinogenesis 
and synaptogenesis, neuronal number, morphology, glucose metabolic rates, and gene  expression1,3. Additionally, 
estrogen depletion has been linked to amyloid-beta (Aβ) plaque accumulation, a hallmark of Alzheimer’s disease 
(AD), in female  animals4,5. However, little is known of how the MT impacts the human brain.
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Brain imaging analyses conducted in post-menopausal women first reported declines in glucose metabolism 
and gray matter volume (GMV), which were modulated by menopause hormone treatment (HT)6,7, indicat-
ing that neuro-endocrine processes retain dynamic properties well into menopause. However, data in women 
undergoing the MT are scarce. We previously reported that, among those with genetic risk factors for AD such 
as apolipoprotein epsilon-4 genotype (APOE-4)8, the MT was associated with lower GMV, hypometabolism, 
and emerging Aβ  deposition9–11. It is unknown whether similar changes occur in women without genetic risks 
for AD, or whether the MT impacts other structural, bioenergetic and cognitive indicators.
Herein, we conducted a multi-modality neuroimaging study of women at different MT stages (pre-, peri-, 
and post-menopause) to investigate MT’s effects on brain’s gray (GM) and white matter (WM) structure, con-
nectivity, energy metabolism, and Aβ deposition. Results indicate that the MT significantly impacts all these 
brain biomarkers in regions involved in higher-order cognitive functions. Effects were independent of age and 
HT use, and were specific to menopausal endocrine aging rather than chronological aging, as determined by 
comparison with age-matched males. Notably, cognition was preserved post-menopause, which correlated with 
GMV recovery and brain adenosine triphosphate (ATP) production, highlighting potential compensatory mecha-
nisms. Finally, Aβ deposition was greater in post-menopausal and peri-menopausal women carrying APOE-4 
genotype, indicating APOE-4 specific effects on AD risk with onset in the peri-menopause.
Results
Participants. A total of 182 cognitively intact 40–65 year-old women were enrolled. Nine participants were 
excluded due to neuropathological conditions encountered in the MR images (n = 7; e.g. neoplastic condition or 
aneurysm), or due to artifacts (n = 2). Three participants with incomplete clinical data and 9 with unclear meno-
pause status were also excluded. Our final sample consisted of 161 women, including 30 pre-menopausal (PRE), 
57 peri-menopausal (PERI), and 74 post-menopausal (POST) participants.
Participants’ characteristics are found in Table 1. There were no group differences in demographic and clinical 
measures except for an age difference between PRE and POST groups. As described in “Methods”, our procedures 
to address age effects included (i) adding age as a confounder in all analyses, and (ii) comparing each MT group 
to an age-matched male group: consisting of 30 males age-matched to the PRE group  (MALEPRE), 50 age-matched 
to the PERI group  (MALEPERI), and 45 age-matched to the POST group  (MALEPOST) (Supplementary Table S1). 
Forty-two percent of participants were APOE-4 positive, with comparable distributions between groups.
Biomarker results. We examined a panel of brain biomarkers examining:
• Structure: GMV and white matter volume (WMV) via Magnetic Resonance Imaging (MRI), and fractional 
anisotropy (FA, an index of WM integrity and structural  connectivity12) via MRI-Diffusion Tensor Imaging 
(DTI);
• Energy metabolism: glucose metabolism (CMRglc) via 18F-fluorodeoxy-2-glucose (FDG) Positron Emission 
tomography (PET), cerebral blood flow (CBF) via Arterial Spin Labeling (ASL), and ATP production via 
31Phosphorus-Magnetic Resonance Spectroscopy (31P-MRS);
• Aβ deposition via 11C-Pittsburgh compound B (PiB) PET.
Table 1.  Participants’ characteristics by menopause status. Clinical measures are means (SD), unless otherwise 
specified. Cognitive measures are age and education-adjusted means (SE). *Different from PRE, p < 0.05.
Pre-menopausal group Peri-menopausal group Post-menopausal group
Clinical and demographic measures
N 30 57 74
Age, years, range 44 (4), 40–53 50 (4), 41–60 57 (4)*, 46–65
Education, years 17 (3) 17 (2) 17 (2)
Ethnicity, % White 80 77 89
MMSE score 29 (1) 29 (1) 29 (1)
APOE ε4 carriers, % positive 43 33 48
Hysterectomy status, % positive 0 6 19
Menopausal hormonal therapy
% Current users 0 13 32
% Past users 0 2 4
Cognitive measures
Global cognition, mean (SE) − 0.11 (0.17) − 0.02 (0.09) 0.06 (0.11)
Adjusted by APOE-4 status − 0.09 (0.17) − 0.03 (0.09) 0.06 (0.11)
Memory, mean (SE) 0.05 (0.20) 0.06 (0.11) 0.02 (0.13)
Adjusted by APOE-4 status 0.07 (0.21) 0.04 (0.11) 0.02 (0.13)
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Unless otherwise specified, all below voxel-based results are significant at p < 0.05, cluster-level corrected for 
family-wise type error (FWE), adjusted for age, APOE-4 status, and modality-specific confounders.
Biomarker differences between MT groups. Structural biomarkers. GMV. MT stage effects were 
observed in inferior temporal gyrus, precuneus, and fusiform gyrus of the right hemisphere (Fig. 1a). On post-
hoc analysis, the temporal cluster reflected lower GMV in the POST group compared to the PRE group, while 
the precuneus and fusiform clusters reflected lower GMV in the PERI group compared to the POST group 
(Fig. 1b, and Supplementary Table S2).
WMV. MT stage effects were observed in anterior and posterior corona radiata, which reflected lower WMV 
in POST versus PRE and PERI groups (Fig. 1c, d, and Supplementary Table S2).
FA. The only cluster showing MT stage effects that survived correction for multiple comparisons was the right 
external capsule. In this cluster, the POST group had lower FA than PERI (cluster extent 71 voxels, x, y, z = 33, 
− 9, − 6, Z = 3.81, p = 0.017; Fig. 1e, f). There was no anatomical overlap between FA and WMV maps, as shown 
in Fig. 1g.
Metabolic biomarkers. CMRglc. MT stage effects were observed in supramarginal gyri, middle and inferior 
temporal gyri (Fig. 2a). On post-hoc analysis, all clusters reflected lower CMRglc in the POST group compared 
to the PRE and PERI groups, and lower CMRglc in right middle temporal gyrus of the PERI compared to the 
PRE group (Fig. 2b, and Supplementary Table S3).
CBF. MT stage effects were observed in supramarginal gyrus, middle and superior temporal gyrus, superior 
and inferior frontal gyrus of both hemispheres, which on post-hoc analysis, reflected higher CBF in POST versus 
PERI (Fig. 2c, d, and Supplementary Table S3).
Figure 2e displays the regional overlap of CMRglc and CBF effects.
ATP production. We examined regional ATP to phosphocreatine (PCr) ratios in parieto-temporal regions 
showing MT-stage effects on CMRglc and CBF (Table 2). Multivariate general linear models (mGLM) showed 
higher ATP/PCr in temporal regions (p’s ≤ 0.047) and borderline higher ATP/PCr in parietal regions (p < 0.12) of 
POST versus PRE groups. Results remained significant adjusting by APOE-4 status (Table 2).
Amyloid-β load. Results are reported in Table 2. Adjusting by age and cerebellar uptake, there were no signifi-
cant differences in PiB uptake between MT groups. However, adding APOE-4 status as a covariate enhanced 
group differences, resulting in higher PiB uptake in POST versus PRE (27%, p = 0.006), and PERI versus PRE 
groups (18%, p = 0.056). PiB differences between PERI and PRE groups were more pronounced among APOE-4 
carriers (Table 2).
Comparisons to age‑matched males. To determine whether MT-stage effects on biomarkers were 
specific for menopause endocrine aging versus chronological aging, we compared each MT group to an age-
matched male group. We first tested for group biomarker differences within the brain regions showing the MT 
group-specific effects reported above. We then tested for group differences in the entire search volume.
Structural biomarkers. GMV. Results are presented in Fig.  3a, and Supplementary Table  S4. Examination 
of brain regions showing MT-stage effects indicated lower GMV in inferior temporal gyrus of the POST group 
compared to  MALEPOST, and lower GMV in precuneus and fusiform gyrus of the PERI group compared to 
 MALEPERI. Across the entire search volume, both POST and PERI groups exhibited additional widespread areas 
of lower GMV compared to males, involving middle and medial temporal (MTL) regions, superior, middle, and 
orbital frontal gyrus, anterior cingulate (ACC), insula, and putamen. The PRE group showed lower GMV versus 
 MALEPRE in MTL, frontal gyrus, putamen, and inferior and middle temporal cortex.
WMV. Results are presented in Fig. 3b, and Supplementary Table S5. In examination of brain regions exhibit-
ing MT-stage effects, lower WMV in corona radiata of the POST group compared to  MALEPOST was evident. In 
the entire search volume, the POST group exhibited additional areas of lower WMV in several tracts including 
superior longitudinal fasciculus (SLF), posterior thalamic radiation, and cortico-spinal tracts. The PERI group 
exhibited a similar pattern of lower WMV compared to  MALEPERI, and the PRE group showed lower WMV in 
internal capsule compared to  MALEPRE.
FA. Results are presented in Fig. 3c, and Supplementary Table S6. Examination of brain regions showing MT-
stage effects revealed higher FA in corona radiata and fornix in the POST group compared to  MALEPOST. There 
were no other regions showing FA differences for POST versus  MALEPOST. The PERI group exhibited higher FA 
in corona radiata, fornix, external capsule and uncinate fasciculus; and lower FA in SLF and posterior thalamic 
radiation compared to  MALEPERI. The PRE group showed higher FA in corona radiata, and lower FA in SLF, 
compared to  MALEPRE.
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Figure 1.  Structural biomarker differences between menopausal groups. (a) Surface maps of regional GMV differences. (b) MRI slice 
overlays and plots representing GMV in temporal and precuneus clusters. (c) Surface maps of regional WMV differences. (d) MRI 
slice overlays and plots representing WMV in anterior and posterior areas averaged between hemispheres. (e) Surface maps of regional 
FA differences. (f) MRI slice overlays and plots representing FA in external capsule. (g) Slice overlays depicting lack of overlap between 
WMV (purple) and FA (yellow) effects. In (a, c, e), SPMs are represented on modality-specific color-coded scales with corresponding 
P values. In (g), Z scores are reported in lieu of p values to enable multi-modality comparison. In (b, d), values are mean (SE). Results 
are adjusted by age and total intracranial volume. Abbreviations FA, fractional anisotropy; GMV, gray matter volume; PERI, peri-
menopause; POST, post-menopause; PRE, pre-menopause; SPMs, statistical parametric maps; WMV, white matter volume.
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Figure 2.  Metabolic biomarker differences between menopausal groups. (a) Surface maps of regional CMRglc 
differences. (b) MRI slice overlays and plots representing CMRglc in temporal and parietal regions. (c) Surface 
maps of regional CBF differences. (d) MRI slice overlays and plots representing CBF extracted in temporal 
and parietal clusters. (e) Slice overlays depicting the overlap between CMRglc (green to red scale) and CBF 
(blue to green scale) effects. (f) In (a, c), SPMs are represented on modality-specific color-coded scales with 
corresponding p values. In (e), Z scores are reported to enable multi-modality comparisons. In (b, d), values 
are mean (SE). Results are adjusted by age and global activity. Abbreviations CBF, cerebral blood flow; CMRglc, 
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Metabolic biomarkers. CMRglc. Results are presented in Fig. 3d, and Supplementary Table S7. Examination 
of brain regions showing MT-stage effects showed lower CMRglc in temporo-parietal areas of the POST group 
compared to  MALEPOST. In the entire search volume, the POST group exhibited additional areas of hypometabo-
lism in superior and middle frontal cortex compared to males. The PERI group showed lower CMRglc in frontal 
Table 2.  Region-of-Interest (ROI) measures by menopausal stage group. APOE-4−, APOE-4 non-carriers; 
APOE-4+, APOE-4 carriers; PERI, peri-menopausal group; POST, post-menopausal group; PRE, pre-
menopausal group; SUVR, standardized uptake value ratio to cerebellar gray matter PiB uptake. Values are 
means (SE), unless otherwise specified. *Different from PRE, p < 0.05.
PRE PERI POST
ATP/PCr measures
Superior temporal gyrus 1.11 (0.05) 1.18 (0.03) 1.26 (0.03)*
Adjusted by APOE status 1.14 (0.04) 1.18 (0.03) 1.24 (0.02)*
Middle temporal gyrus 1.09 (0.04) 1.13 (0.03) 1.20 (0.02)*
Adjusted by APOE status 1.10 (0.03) 1.14 (0.02) 1.19 (0.02)*
Inferior temporal gyrus 1.07 (0.04) 1.11 (0.02) 1.13 (0.02)*
Adjusted by APOE status 1.07 (0.03) 1.10 (0.02) 1.14 (0.02)*
Inferior parietal lobule 0.77 (0.06) 0.76 (0.05) 0.83 (0.04)
Adjusted by APOE status 0.78 (0.04) 0.75 (0.03) 0.83 (0.03)*
Amyloid-β load
AD-mask SUVR 1.01 (0.12) 1.20 (0.06) 1.27 (0.07)
Adjusted by APOE status 1.00 (0.09) 1.21 (0.06) 1.29 (0.06)*
AD-mask SUVR by APOE-4 status
APOE-4− 0.94 (0.12) 1.14 (0.07) 1.32 (0.07)*
APOE-4+ 1.07 (0.12) 1.32 (0.11)* 1.25 (0.08)*
Figure 3.  MRI slice overlays displaying biomarker differences between each MT group and males in the 
corresponding age ranges: (a) Lower GMV in (left) POST, (middle) PERI, and (right) PRE groups versus males. 
(b) Lower WMV in (left) POST, (middle) PERI, and (right) PRE groups versus males. (c) Higher FA in (left) 
POST, and (middle) PERI versus males; (right) no differences between PRE and males. (d) Lower CMRglc in 
(left) POST, (middle) PERI, and (right) PRE groups versus males. (e) Higher CBF in (left) POST, (middle) PERI, 
and (right) PRE groups versus males. (f) SPMs are represented on modality-specific color-coded scales with 
corresponding Z scores to enable multi-modality comparisons. Abbreviations See legend to Figs. 1 and 2.
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cortex and insula versus  MALEPERI, and the PRE group showed lower CMRglc in left supramarginal gyrus versus 
 MALEPRE.
CBF. Results are presented in Fig. 3e, and Supplementary Table S8. Examination of brain regions exhibiting 
MT-stage effects showed elevated CBF in frontal regions of POST versus  MALEPOST. In the entire search volume, 
the POST group also exhibited lower CBF in ACC, MTL, and basal ganglia compared to males. Likewise, PERI 
and PRE groups exhibited areas of higher and lower CBF compared to males, chiefly lower CBF in ACC, medial 
and superior temporal gyrus, and basal ganglia, and higher CBF in parietal lobe.
ATP production. We investigated ATP/PCr using two separate mGLMs: model 1 included regions with 
higher CBF in POST versus  MALEPOST (ACC, insula and temporo-parietal regions); model 2 included regions 
with lower CMRglc and CBF in POST versus  MALEPOST (frontal areas). Results are presented in Table 3. With 
and without adjustment by APOE-4 status, the POST group had higher ATP/PCr than  MALEPOST in model 1 
(p ≤ 0.003) and borderline higher ATP/PCr in model 2 (p ≤ 0.082), and the PERI group had higher ATP/PCr than 
 MALEPERI in model 2 (p ≤ 0.049). There were no differences between PRE and  MALEPRE.
Amyloid-β load. POST and PERI groups exhibited higher PiB uptake in AD-mask than  MALEPOST and 
 MALEPERI, respectively (p’s ≤ 0.001), while no differences were found between PRE and  MALEPRE (Table  3). 
These effects remained unchanged including APOE-4 status as a covariate, which enhanced differences between 
PERI and  MALEPERI APOE-4 carriers (p = 0.020). PiB differences between PERI and  MALEPERI were more pro-
nounced among APOE-4 carriers (Table 3).
Biomarker changes post‑menopause. To examine whether biomarker effects were persistent post-
menopause, and to test their specificity for menopause endocrine aging versus chronological aging, we per-
formed 2-year follow-up volumetric MRI and FDG-PET scans in 17 POST and 12  MALEPOST (Supplementary 
Table S9). We first tested for changes in biomarkers within the brain regions showing POST-specific effects, and 
secondly, in the entire search volume.
Examination of brain regions exhibiting POST-stage effects on GMV indicated no GMV changes in inferior 
temporal and fusiform gyri, and GMV increases in the precuneus of the POST group (Fig. 4a, d; and Supplemen-
tary Table S10). There were no GMV changes in precuneus of the  MALEPOST group, suggesting POST-specific 
GMV recovery. In the entire search volume, both POST and  MALEPOST groups showed GMV declines in right 
frontal gyrus, which did not differ between the groups (Supplementary Table S10).
No significant WMV changes were observed in the POST group, or in comparison to  MALEPOST (Fig. 4b, d).
Table 3.  Regions-of-interest (ROI) measures by age-matched male group comparisons. MALEPRE, males 
age-matched to PRE;  MALEPERI, males age-matched to PERI;  MALEPOST, males age-matched to POST; PERI, 
peri-menopausal group; POST, post-menopausal group; PRE, pre-menopausal group. Values are means (SE). 
*Different from age-matched males, p < 0.05.
PRE MALEPRE PERI MALEPERI POST MALEPOST
ATP/PCr measures
Anterior cingulate cortex 1.06 (0.07) 1.11 (0.07) 1.10 (0.04) 1.12 (0.05) 1.12 (0.04) 1.12 (0.05)
Adjusted by APOE-4 status 1.05 (0.07) 1.12 (0.07) 1.11 (0.04) 1.10 (0.05) 1.11 (0.04) 1.13 (0.05)
Insula 1.21 (0.06) 1.29 (0.07) 1.24 (0.04) 1.24 (0.04) 1.26 (0.03)* 1.21 (0.05)
Adjusted by APOE-4 status 1.20 (0.06) 1.30 (0.06) 1.24 (0.04) 1.23 (0.04) 1.27 (0.03)* 1.22 (0.05)
Inferior parietal lobule 0.78 (0.07) 0.85 (0.08) 0.76 (0.04) 0.84 (0.04) 0.83 (0.03) 0.86 (0.04)
Adjusted by APOE-4 status 0.77 (0.08) 0.86 (0.08) 0.76 (0.04) 0.84 (0.04) 0.83 (0.03) 0.86 (0.04)
Middle temporal gyrus 1.10 (0.04) 1.17 (0.05) 1.15 (0.02) 1.12 (0.3) 1.19 (0.02)* 1.10 (0.03)
Adjusted by APOE-4 status 1.10 (0.04) 1.18 (0.04) 1.15 (0.02) 1.12 (0.3) 1.19 (0.02)* 1.10 (0.03)
Medial temporal lobe 1.16 (0.05) 1.24 (0.05) 1.22 (0.03) 1.20 (0.04) 1.21 (0.03) 1.19 (0.04)
Adjusted by APOE-4 status 1.15 (0.05) 1.26 (0.05) 1.22 (0.03) 1.20 (0.04) 1.22 (0.03) 1.19 (0.04)
Medial frontal gyrus 1.05 (0.06) 0.99 (0.06) 1.04 (0.03) 0.98 (0.04) 1.07 (0.03)* 0.95 (0.04)
Adjusted by APOE-4 status 1.04 (0.06) 1.01 (0.06) 1.05 (0.03) 0.97 (0.04) 1.07 (0.03)* 0.96 (0.04)
Superior frontal gyrus 0.95 (0.05) 0.86 (0.06) 0.94 (0.03)* 0.84 (0.03) 0.96 (0.03)* 0.83 (0.04)
Adjusted by APOE-4 status 0.94 (0.05) 0.87 (0.05) 0.95 (0.03)* 0.84 (0.04) 0.96 (0.03)* 0.84 (0.04)
Amyloid-β load
AD-mask SUVR 1.01 (0.05) 0.92 (0.05) 1.20 (0.05)* 0.92 (0.06) 1.29 (0.05)* 0.93 (0.06)
Adjusted by APOE-4 status 1.01 (0.05) 0.92 (0.05) 1.21 (0.05)* 0.91 (0.06) 1.29 (0.05)* 0.93 (0.06)
AD-mask SUVR by APOE-4 status
APOE-4− 0.94 (0.07) 0.86 (0.07) 1.14 (0.06) 0.88 (0.08) 1.32 (0.07)* 0.93 (0.09)
APOE-4+ 1.07 (0.07) 0.96 (0.08) 1.32 (0.09)* 0.93 (0.10) 1.25 (0.05)* 0.95 (0.10)
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Examination of temporo-parietal regions that were hypometabolic in the POST group versus PRE and PERI 
groups showed CMRglc declines in left inferior parietal lobule and not in other areas of the POST group (Fig. 4c, 
d; Supplementary Table S11). Parietal CMRglc declines were significant compared to  MALEPOST. In the entire 
search volume, there were no further longitudinal group differences.
Summary of biomarker findings. The main biomarker findings of this study are summarized in Fig. 5.
Sensitivity analysis. We performed a sensitivity analysis to test for effects of HT use and hysterectomy 
status on biomarker data. Results are presented in Supplementary Appendix. Briefly, including HT use and 
Figure 4.  Longitudinal biomarker changes post-menopause. (a) Surface maps of GMV change. (b) Surface 
maps of WMV change. (c) Surface maps of CMRglc change. (d) Plots representing mean (SE) biomarker levels 
at baseline (POST) versus 2-year follow-up (POST + 2) in the subset of POST participants with longitudinal 
brain scans. Surface maps are represented on modality-specific color-coded scales with corresponding p values. 
See legends to Figs. 1 and 2.
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hysterectomy status as covariates left MT effects on brain biomarkers substantially unchanged. As compared to 
HT users, non-users exhibited lower GMV in inferior temporal gyrus, and lower CMRglc in parietal regions, 
independent of hysterectomy status. Restricting analysis to HT non-users confirmed results from the entire 
cohort, with two exceptions: CBF differences between MT groups were more pronounced among non-users, and 
FA differences between PERI and POST groups did not reach significance.
Associations between biomarkers and cognition. There were no significant differences in cognitive 
scores between MT groups (Table  1), or between each MT group and the corresponding age-matched male 
group (Supplementary Table S12). As shown in Supplementary Table S13, in the POST group, precuneus GMV 
was positively associated with memory scores at cross-section (r = 0.311, p = 0.007) and longitudinally (r = 0.521, 
p = 0.032). ATP/PCr in temporo-parietal regions was positively associated with global cognition (Rho = 0.323, 
p = 0.027). There were no significant associations between cognitive scores and regional biomarkers among PRE 
and PERI groups (Supplementary Table S13).
Discussion
Outcomes of this multi-modality neuroimaging analyses demonstrate that MT stage has pronounced effects 
on human brain’s structure, connectivity, and energy metabolism, and provide a neurological framework for 
both vulnerability and resilience. Effects were most pronounced in regions subserving higher-order cognitive 
processes, and were independent of age, APOE-4 status, HT usage, and hysterectomy status. Comparisons 
to age-matched males provided further evidence that neuroimaging biomarker effects were specific to meno-
pausal endocrine aging rather than to chronological aging. In most brain regions and across modalities, brain 
biomarkers stabilized or recovered post-menopause. Cognitive preservation post-menopause correlated with 
GMV recovery and brain ATP production, highlighting possible compensatory mechanisms. In parallel to the 
adaptive process, Aβ deposition was more pronounced in PERI and POST women positive for APOE-4 genotype, 
indicating specificity for AD risk with onset in the peri-menopause.
The MT is a normal physiological event. However, while the majority of women undergo menopause without 
long-term adverse  effects1, many are vulnerable to the neurological shifts that can occur during this transition, 
experiencing bothersome  symptoms2 as well as a higher risk of depression, anxiety, and  AD13. Preclinical work 
indicates that the brain has the ability to compensate for changes in estrogen levels and estrogen receptor activ-
ity during the  MT1. In some instances, however, compensatory responses are diminished, lacking, or limited to 
some estrogen-regulated  networks1, which may account for the complex MT phenotype observed in  women2. 
Investigation of compensatory responses is still in the early  stages1, though clinical observations suggest that 
gradual hormonal changes during spontaneous MT may allow “brain resetting”, e.g. neuronal adaptations to 
the hypo-estrogenic post-menopausal  state1,14,15. Brain adaptation may account for the easing of menopausal 
symptoms like hot flashes, which tend to resolve 2–7 years into  menopause2. Present neuroimaging results pro-
vide novel neurophysiological evidence for post-menopausal brain adaptation in humans, encompassing brain 
structure, connectivity and bioenergetics, and preservation of cognitive function.
Our results have several implications. First, compared to age-matched males, POST and PERI groups exhib-
ited lower GMV in several cortical regions and subcortical structures such as hippocampus, amygdala, and 
Figure 5.  Summary of brain biomarker effects during the menopause transition. This figure summarizes the 
main results of the study by mapping estimated brain biomarker outcomes from pre-menopausal to peri-
menopausal and post-menopausal stages. Biomarker measures extracted from representative clusters for each 
modality are displayed on a standardized scale and normalized to pre-menopausal levels to enable examination 
of the magnitude of biomarker effects by menopausal stage and across modalities.
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thalamus. However, GMV generally stabilized post-menopause and selectively recovered in precuneus, an asso-
ciative cortical area involved in social processes, episodic memory, and information  integration16. On average, 
in the POST group, GMV in precuneus (a) was higher than the PERI group, (b) was comparable to age-matched 
males, and (c) increased over a 2-year span, a change that was not observed in males, indicating POST-specific 
recovery. Further, among POST participants, GMV in precuneus correlated with memory scores at cross-section 
and longitudinally, indicating that this area undergoes structural changes that are influenced by MT and have 
cognitive implications. Brain imaging studies of pregnancy, the other female-specific neuro-endocrine transi-
tion, also report dynamic GMV changes in precuneus, which are thought to reflect reduced neurogenesis in 
late pregnancy, followed by restoration by the time of  weaning17. Although neurogenesis decreases with  aging18, 
similar mechanisms may play a role in the brain’s adaptation to the post-menopausal stage. Notably, the observed 
MT-related anatomical pattern maps onto estrogen-regulated  systems1 and displays notable similarities to the 
neural networks impacted by  pregnancy19.
MT stage also influenced WMV within major tracts connecting extensive parts of the cerebral cortex and 
subcortical regions. Both POST and PERI groups exhibited widespread WMV loss compared to age-matched 
males, with the POST group also exhibiting lower WMV in corona radiata compared to PRE and PERI groups. 
In spite of the WMV loss, all MT groups exhibited higher FA than males in corona radiata, as well as in fornix 
of the POST group, and in fornix, uncinate fasciculus and external capsule of the PERI group. PERI and PRE 
groups also exhibited some clusters with lower FA than males, involving chiefly SLF, whereas the POST group 
showed no deficits. To our knowledge, there are no previous DTI studies of the MT. However, there is evidence 
for sex differences in WM microstructure that vary with age and endocrine aging status. Most DTI studies on the 
entire age range found that males have generally higher FA than females in WM tracts such as  SLF20, as in our 
comparisons with PERI and PRE groups. In contrast, during puberty (the first neuro-endocrine transition for 
both genders), females display higher FA than males in several WM tracts including corona radiata and  fornix21. 
Animal studies report that pregnancy is also accompanied by increased regional water  diffusivity22. While FA 
has a number of determinants, the principle factors are myelination and tissue architecture, with the inference 
that higher FA represents more “efficient” WM  organization12. As such, our findings suggest greater efficiency of 
a smaller corona radiata and fornix post-menopause, raising the possibility that MT is accompanied by further 
refinement of these regions’ connectivity. Longitudinal studies are warranted to map FA changes during the MT 
and in relation to other biomarkers.
The MT also impacted brain energetics on multiple levels. The POST group, and to a lesser extent the PERI 
group, exhibited hypometabolism in parieto-temporal cortices, consistent with previous reports in women at 
risk for  AD9–11. However, in the present study, regional CMRglc largely plateaued post-menopause, suggesting 
adaptation to a new metabolic baseline after prolonged estrogen deficiency. Additionally, CBF and ATP produc-
tion in temporo-parietal regions were elevated post-menopause, and ATP levels positively correlated with global 
cognition. Our findings of higher CBF in women than in men are consistent with the  literature23, and further 
indicate that MT modulates CBF sex differences in midlife. To our knowledge, there are no previous studies of 
MT effects on brain ATP production in humans. Altogether, present results provide novel evidence for in vivo 
neurovascular-neurometabolic dissociations during the MT. Typically, regional brain activity, CMRglc, and 
CBF are  coupled24. Dissociation can occur with aging, pathology, and  inflammation24, or as a compensatory 
 response25. While data in humans are scarce, preclinical evidence indicates that estrogen loss during MT triggers 
CMRglc  declines26, prompting an adaptive reaction to increase ketone bodies utilization as an alternative fuel 
for  ATP27. Continued reliance on ketones leads to compromised mitochondrial function, WM catabolism, and 
cellular apoptosis in  animals26,27. In light of preclinical work, the higher CBF and ATP levels observed in our 
POST women may reflect a compensatory reaction to glucose hypometabolism, as well as a means to increase 
ketone metabolism.
We previously reported lower peripheral mitochondrial cytochrome oxidase activity (COX) in POST versus 
PRE women at risk for  AD28. Herein, we investigated mitochondria ATP production in brain, which was higher 
in POST women independent of APOE-4 status, suggesting different mitochondrial activity profiles in brain and 
periphery. Animal models of menopause show dynamic relationships between central and peripheral metabolic 
systems, which tend to shift from uncoupled to coupled under metabolic  stress29. Although brain mitochondria 
might eventually falter in older POST women, the positive associations between ATP production and global cog-
nition suggest a recovery mechanism, at least in midlife. As aging and menopause differ to some extent between 
humans and animals, the neuro-energetics of menopause are also likely to differ – in this case, by supporting 
women’s ability to transition into late life with preserved cognition, as discussed below.
In parallel to the hypothesized adaptive process, POST and PERI groups, especially APOE-4 carriers, exhib-
ited higher Aβ deposition compared to the PRE group and to age-matched males. While Aβ deposition was mild, 
this data is consistent with previous studies of women at risk for  AD9–11, and support evidence that interactions 
between age, female gender and APOE-4 increase AD vulnerability during peri-menopause30. Chronologically, 
MT maps onto the preclinical phase of AD, which begins decades prior to symptom  onset31. The earlier onset 
of, and longer exposure to Aβ pathology may help explain the higher prevalence of AD in females, with POST 
women comprising over 60% of all  cases32. It warrants emphasis that reproductive aging is not uniformly associ-
ated with AD risk. While some women in our cohort might eventually develop AD, for others, Aβ deposition 
could reflect accelerated biological aging due to hormonal declines  instead33. In fact, over 20% of healthy elderly 
display moderate cerebral Aβ burden and no  dementia31.
The proportion of APOE-4 carriers in our study was 42%, which is higher than the 15–30% observed in the 
general  population34. Many of our participants volunteer because of concerns about cognitive functioning, which 
tend to be more frequent among APOE-4  carriers35. As such, our cohort may be self-enriched with individuals 
at higher a priori risk of AD. Although our results were independent of APOE-4 status, more studies are needed 
to replicate these findings in community-dwelling individuals randomly recruited from the population.
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The observed MT effects were independent of HT and hysterectomy status, though HT use was associated 
with mild beneficial effects on GMV and CMRglc, consistent with some clinical  trials6. Whether HT provides 
protection against cognitive aging and AD remains unclear. Observational studies generally found positive 
effects on cognition across multiple HT  regimens36, whereas clinical trials of late POST women aged 65 or older 
reported an increased dementia risk with estrogen-plus-progestin HT, and no effects with estrogen-alone37, while 
studies of early POST women observed no adverse or beneficial effects on  cognition38,39. Overall, HT’s efficacy 
is thought to depend on timing of treatment initiation with respect to age at menopause, with benefits pertain-
ing to early initiation, especially after induced  menopause7,37. Our neuroimaging results point to the MT as a 
dynamic neurological process and, therefore, a window of vulnerabilities and opportunities when the human 
brain is influenced by biochemical adjustments, but is also likely to be receptive to interventions. More studies 
are needed to test the efficacy of HT instituted prior to menopause, and in relation to brain biomarker levels.
In our study, POST participants did not exhibit impaired cognitive performance as compared to the other 
groups. While self-reports of poor memory and concentration are common in women undergoing  MT2, meno-
pause itself hasn’t been associated with clinically significant functional impairment or deficits on cognitive 
 testing40. Further, it is well-documented that women perform better than men on several cognitive domains 
across the adult lifespan– an advantage that seems to persist even after a dementia  diagnosis41. Lack of cognitive 
decline may seem in contrast with neuroimaging findings of extensive MT-stage effects on brain biomarkers. In 
the present study, GMV recovery and ATP production positively correlated with cognitive scores in the POST 
group. While this awaits confirmation, present results provide neurophysiological insights on brain adaptation 
during the MT, which may at least in part, account for the lack of cognitive impairment among POST  women40. 
Large-scale epidemiological studies reported a decrement in cognitive performance during the peri-menopause, 
followed by a rebound to pre-menopausal levels in post-menopause42. This is consistent with the post-meno-
pausal brain biomarker recovery observed in our study. Additionally, studies that differentiated between early 
and late menopausal stages reported subtle yet transitory cognitive changes during the  MT43, which have yet to 
be investigated with neuroimaging. However, it is possible that brain and cognitive aging trajectories may differ 
among MT women depending on genetic predisposition, medical history, and environmental influences. More 
longitudinal imaging studies with larger samples are warranted to address these questions. Additionally, as our 
cohort was highly educated, the observed lack of cognitive deficits may not be generalizable to women with dif-
ferent educational or socio-economical background.
Another limitation of this study is the low percentage of minority participants, which limits the generaliz-
ability of our findings. Today, no brain imaging studies have been conducted to investigate MT effects on brain 
biomarkers based on ethnicity. Multiple studies have indicated increased frequency and severity of menopau-
sal symptoms, particularly vasomotor symptoms, with greater prevalence in African-American and Hispanic 
 women44, which strongly argues for studies that specifically address differences in MT-associated biomarker 
outcomes across ethnic groups.
From a methodological perspective, we examined statistically powered groups of women at different MT 
stages, paired with age correction procedures including comparisons to age-matched males and longitudinal 
evaluations in a subset of participants. Nonetheless, a causal link between MT and brain biomarkers cannot 
be unequivocally established. We chose this study design because the timing of menopause is highly variable, 
with a median age at menopause of 51 years, and a distribution of 40–58  years2. Longitudinal studies may 
require > 10 years of follow-ups to capture the effects of MT on brain biomarkers. While studies of surgical 
menopause ideally reduce follow-up times, the procedure seems associated with different, possibly more severe 
 outcomes45,46. Longitudinal studies are warranted to replicate our findings and test for differential effects of 
induced and spontaneous menopause.
Determination of MT status was based on established diagnostic  criteria47. Nonetheless, some PERI may 
have been early POST, while some early POST could have been late PERI. This would, however, conservatively 
reduce power in detecting MT-stage effects. Considering the hormonal changes women experience during 
MT, and the observed biomarker effects, we attribute our results to the endocrine climate of menopause. Our 
analyses were corroborated by testing of males of similar demographic and socio-economical characteristics. 
Future studies tracking changes in hormones, medical status, and lifestyle are needed to clarify the complex 
relationships between MT and brain  aging13, and identify which factors impact successful versus unsuccessful 
brain adaptation post-menopause.
Overall, present findings show that human menopause is a dynamic neurological transition that reshapes the 
neural landscape of the female brain during midlife endocrine aging, and provide preliminary evidence for an 
adaptive process serving the transition into late life.
Methods
Participants. This is a non-randomized natural history non-treatment study of healthy, cognitively normal 
female and male participants ages 40–65 years at different menopausal stages, recruited at Weill Cornell Medi-
cine (WMC) and NYU School of Medicine between 2015 and 2020. Participants were recruited by self-referral, 
flyers, and word of mouth, as  described9–11. Pre-established exclusion criteria included medical conditions that 
may affect brain structure or function (e.g. stroke, any neurodegenerative diseases, major psychiatric disorders, 
hydrocephalus, white matter lesions suggestive of demyelinating disease such as Multiple Sclerosis, intracranial 
mass and infarcts on MRI), use of psychoactive medications, and contraindications to MRI or PET. Participants 
had Mini Mental Status Exam ≥ 27 and normal cognitive performance for age and  education9–11.
The patients’ sex was determined by self-report. APOE genotype was assessed using quantitative Polymerase 
Chain Reaction (qPCR)  procedures9–11. Participants carrying one or two copies of APOE-4 allele were grouped 
as carriers, and compared to non-carriers.
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Standard protocol approvals, registrations, and patient consents. All methods were carried out in accordance 
with relevant guidelines and regulations. All experimental protocols were approved by the WMC and NYU 
Institutional Review Boards. Written informed consent was obtained from all participants.
Cognitive testing. Our neuropsychological testing battery included tests measuring three cognitive domains: 
memory (immediate and delayed recall of a paragraph and paired associates), higher-order processing (block 
design tests), and language (object naming)9–11. We computed (i) a global cognitive score by creating Z-scores 
within each domain and averaging across the domains; and (ii) a memory score by creating Z-scores for each 
memory test and averaging across tests.
Menopause assessments. Determination of menopausal status was based on the Stages of Reproductive Aging 
Workshop (STRAW)  criteria47 and corroborated by means of hormone assessments. Female participants were 
classified as regular cyclers (PRE), irregular cyclers (PERI), and no cycle for 12 or more months (POST).
Brain imaging acquisition and analysis. All participants underwent structural MRI, and 160 partici-
pants received 18F-FDG and 11C-PiB PET at WMC. In 2017, we started acquiring DTI, ASL, and MRS scans, 
which have been done on 100 participants.
Our protocol included three MRI sequences on a 3.0 T G.E. Discovery MR750 scanner: (a) sagittal T1-MRI 
[Brain Volume Imaging (BRAVO); 1.0 × 1.0 ×1.0 mm resolution, 8.2 ms repetition time (TR), 3.2 ms echo time 
(TE), 25.6 cm field of view (FOV), 256 × 256 matrix] used to estimate GMV and WMV; (b) DTI scan [b = 0 s/
mm2, b = 1000 s/mm2 55-directions, 8000 ms TR , 65 ms TE, 256 × 256 matrix, 0.9 × 0.9 ×1.8 mm resolution]; (c) 
ASL scan [pseudo-continuous technique with 4851 ms TR, 10.6 ms TE, 4 averages, 24 cm FOV, 2.0 × 2.0 × 3.8 mm 
resolution] used to estimate CBF using arterial blood  water48.
31P-MRS was acquired on the GE scanner using a dual tuned 32-channel 31P/1H quadrature head coil [2048 
points, 5000 Hz sweep width, 2000 ms TR, 2 averages, 55° flip angle at 51.3 MHz, 24 cm FOV] to assess mito-
chondrial function in brain through the mapping of intracellular ATP and PCr  levels49,50. A higher ATP/PCr 
ratio reflects greater ATP production relative to  utilization51. Shimming was performed using a 1H single voxel 
technique placed over the entire brain. Raw data was processed using Hamming and Fermi k-space filters, 20 Hz 
exponential filtering and zero-filling in time, x and y-domains prior to 3D Fast Fourier Transformation. The PCr 
peak is set at 0.0 ppm and susceptibility corrections performed. Baseline correction was applied by an experienced 
analyst (JPD). This resulted in a 16 × 16 image of 1.5 × 1.5 × 3.0 cm voxels with the signal intensity in each voxel 
corresponding to the peak area of the 31P metabolite. The central 4 slices of Chemical Shift Imaging (CSI) data 
were then registered to the BRAVO sequence.
PET scans were acquired on a Siemens BioGraph mCT 64-slice PET/CT operating in 3D mode [70 cm 
transverse FOV, 16.2 cm axial FOV] following standardized  procedures9–11. Summed images were obtained 
40–60 min post-injection of 5 mCi of 18F-FDG, and 60–90 min post-injection of 15 mCi of 11C-PiB. All images 
were corrected for attenuation, scatter and decay, and smoothed for uniform  resolution52.
Two-year follow-up volumetric MRI and FDG-PET scans were performed on 17 POST women (age at base-
line scan: 57 ± 3 years; time to follow-up: 2.2 ± 0.4 years) and 12 males within the same age range (age at baseline: 
56 ± 4 years, time to follow-up: 2.4 ± 0.4 years) using the same protocol and equipment as the baseline exams.
Multiparametric mapping. All images were processed in Statistical Parametric Mapping (SPM12, (https:// www. 
fil. ion. ucl. ac. uk/ spm/ softw are/ spm12/) and Matlab 7.8, using a fully automated image processing  pipeline9–11. 
For each participant, scans were co-registered to the T1-MRI and to each other using the Normalized Mutual 
Information  routine53. Volumetric scans were processed with voxel-based morphometry (VBM), including Jaco-
bian modulation to restore volumes using the unified segmentation algorithm, DARTEL normalization of the 
segments, and application of an 8 mm full-width at half maximum (FWHM) smoothing  kernel53. Co-registered 
DTI, ASL, and PET scans were spatially normalized using subject-specific transformation matrices obtained 
from the corresponding MRI and smoothed at 10-mm FWHM. For longitudinal analysis, each participant’s 
MRIs were processed using longitudinal routines incorporating rigid-body registration, intensity inhomogene-
ity correction, and nonlinear diffeomorphic  registration53. Co-registered follow-up PET were processed using 
the baseline MRI as the anchor.
ATP/PCr and PiB uptake were quantified using FreeSurfer 6.0 and Desikan-Killiany Atlas-based cortical 
 ROIs54,55 applied to the aligned MRI. For PiB analysis, we created an AD-mask by averaging parietal, temporal, 
frontal, posterior cingulate and precuneus  ROIs56,57. PiB uptake in AD-mask was normalized to cerebellar GM 
uptake obtained via FreeSurfer.
Statistical analysis. Analyses were performed in SPSS v.25 and SPM12. Clinical, demographic and cogni-
tive measures were examined with General Linear Models (GLM) or Chi-squared tests at p < 0.05.
To address the age difference between POST and PRE groups  we11,58: (a) used box plots and frequency dia-
grams to ensure that we had sufficient age overlap among women of different MT statuses, which enabled us 
to examine the effects of endocrine aging separately from those of chronological aging; (b) included age as a 
covariate in all analyses; (c) compared each MT group to an age-range matched male group  (MALEPRE,  MALEPERI, 
 MALEPOST); and (d) compared 2-year MRI and FDG-PET changes in a subset of POST women and  MALEPOST.
All images were analyzed using SPM12, except for MRS and PiB-PET ROI data which were examined using 
SPSS, as described below. SPM12 analyses were adjusted by age, APOE-4 status, and modality-specific confounds, 
e.g. GMV, WMV and FA were adjusted by total intracranial volume (TIV) obtained via Freesurfer, CMRglc by 
global metabolic activity, CBF by global CBF. Statistical maps were conservatively obtained by first applying an a 
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priori masking image including regions involved in the brain estrogen network with known cognitive  functions1, 
and then a stringent cluster-level FWE correction at p < 0.05, with cluster extent ≥ 20 voxels. The masking image 
comprised anterior and posterior cingulate cortex; fusiform gyrus; inferior and medial orbitofrontal cortex; 
inferior, medial, middle and superior frontal cortex; inferior, middle, and superior temporal gyrus; inferior and 
superior parietal lobule; insula; medial temporal lobe; precuneus; putamen; and thalamus. For WM analysis, 
the brainstem was also included. Further, results were examined after application of an a priori GM or WM 
mask to restrict analysis to GM or WM fiber voxels, respectively. Identification of GM clusters was made using 
MNI coordinates, and of WM clusters by reference to the Johns Hopkins University White-Matter Labels  atlas59.
In figures, statistical parametric maps and surface maps were obtained using SPM12 and SurfRend v.1 (http:// 
spmsu rfrend. sourc eforge. net/).
Biomarker differences between MT groups. For SPM12 analyses, we used full factorial models to test for bio-
marker differences between MT groups. If a significant main effect was found, we then proceeded to separately 
examine the directionality of biomarker differences between paired groups using post-hoc t-contrasts. For all 
biomarker modalities, statistical parametric maps of significant results were saved as masking images, which 
were then used as implicit masks of MT stage-specific regional biomarker effects in subsequent analyses (see b 
and c, below). For example, the POST group showed larger GMV in precuneus compared to PERI. The precu-
neus cluster was saved as a masking image for further examination of POST and PERI-specific GMV effects in 
this region.
For ROI analyses, we used (i) mGLMs with post-hoc Sidak tests to test for group differences in ATP/PCr in 
regions showing MT effects on CMRglc and CBF (e.g. temporo-parietal regions), adjusting by age and APOE-4 
status as covariates, at p < 0.05; and (ii) GLMs with post-hoc Sidak tests to examine AD-mask PiB uptake for MT 
group effects, and for APOE-4 effects by (i) examining APOE-4 status as a covariate; (ii) testing for interactions 
between MT and APOE-4 status; and (iii) for MT effects within each APOE-4 subgroup, at p < 0.05.
Comparisons to age-matched males. For SPM12 analyses, we used two-sample t-tests to compare each MT 
group to the corresponding age-matched male group, using the same confounders as above. For all biomarker 
modalities, our main endpoint was detection of sex-related biomarker differences within the implicit masks of 
MT stage-specific effects described in (a). For example, we used the precuneus cluster described above to test for 
GMV differences between POST and PERI groups and corresponding age-matched male groups. Comparison 
to  MALEPERI confirmed presence of lower precuneus GMV in the PERI group, while comparison to  MALEPOST 
showed no significant differences in precuneus of the POST group, suggesting POST-specific GMV recovery. As 
this analysis was restricted to specific clusters, our secondary endpoint was detection of group differences in the 
entire search volume.
For ROI analyses, we used (i) mGLMs with post-hoc Sidak tests to test for ATP/PCr group differences in 
regions showing CMRglc and CBF differences between POST and  MALEPOST; and (ii) GLMs with post-hoc Sidak 
to examine AD-mask PiB uptake for group effects and for APOE-4 status effects (as described above), at p < 0.05.
Biomarker changes post-menopause. We investigated whether the structural and CMRglc effects of menopause 
were persistent 2-years after the first examination in a subset of POST and  MALEPOST. Voxel-based changes in 
GMV, WMV and CMRglc were examined by means of post-hoc t-tests on the baseline versus 2-year follow-up 
scans for each group, and by comparing the maps of change between groups, using SPM12. This analysis allowed 
us to identify brain regions showing (i) significant biomarker changes over time in each group, and (ii) different 
rates of change in POST versus  MALEPOST.
Our main endpoint was detection of biomarker changes within the implicit masks of POST-specific regional 
effects, as described in (a). Therefore, we first tested for longitudinal changes within those pre-specified regions 
of the POST group, and then compared the rate of change in those regions between POST and  MALEPOST. For 
example, the POST group showed larger precuneus GMV compared to PERI. Longitudinally, the POST group 
showed increased precuneus GMV over time, whereas  MALEPOST did not, supporting evidence of POST-specific 
GMV recovery in this region. We then tested for longitudinal differences in the entire search volume, e.g. bio-
marker changes outside of the implicit masks. Results were examined at p < 0.05, cluster-level corrected, adjusting 
for time to follow-up and modality-specific confounds.
Cognitive measures: group effects and biomarker associations. We examined cognitive measures for differences 
across groups using Kruskal–Wallis non-parametric tests for global cognition as this measure did not follow a 
normal distribution, and GLMs with post-hoc Sidak tests for analysis of memory scores, adjusting by age, educa-
tion, and APOE-4 status, at p < 0.05. Cognitive measures were then tested for correlations with biomarker data. 
Since cognitive measures were preserved in the POST group, we tested for associations between cognitive meas-
ures and regional biomarkers showing preservation in the POST group, e.g. precuneus GMV, temporo-parietal 
ATP/PCr and CBF. For descriptive purposes, we examined these associations also among PRE and PERI groups. 
Spearman’s Rho tests were used to test for correlations with global cognition, and Pearson’s r tests for correlations 
with memory scores, at p < 0.05, 2-tailed.
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